Comparison of cardiac dysfunction in thalassemia major patients using deferoxamine or deferiprone as an iron-chelating agent
Background In thalassemia major (TM) patients, major mortality is due to cardiac hemosiderosis. Several types of iron chelating agent available recently are given to overcome this problem Objective To compare cardiac dysfunction in thalassemia major patients who used subcutaneous deferoxamine (DFO)...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Indonesian Pediatric Society Publishing House
2012-10-01
|
Series: | Paediatrica Indonesiana |
Subjects: | |
Online Access: | https://paediatricaindonesiana.org/index.php/paediatrica-indonesiana/article/view/473 |
Summary: | Background In thalassemia major (TM) patients, major mortality
is due to cardiac hemosiderosis. Several types of iron chelating
agent available recently are given to overcome this problem
Objective To compare cardiac dysfunction in thalassemia major
patients who used subcutaneous deferoxamine (DFO) to those
who used oral deferiprone (DFP) as an ironchelating agent.
Methods This crosssectional study was held at the Thalassemia
Center, Department of Child HealthCipto Mangunkusumo
Hospital (DCHCMH), Jakarta. We included TM patients aged
1O18 years Mth a mean pretransfused hemoglobin level of 2:.7
g/dL in the prior year, and who had used DFO or DFP for at
least 1 year v.ith good compliance, at a standard dose of DFO at
40-60 mg/kg/day for 5 days a week or DFP at 50-100 mg/kg/day.
We excluded TM patients v.ith congenital heart disease or overt
heart failure. Transthoracal echocardiography was performed at
the Integrated Cardiac Service, CMH by a pediatric cardiologist
using the conventional method and tissue Doppler imaging (TD I)
consecutively, and within 2 weeks of the subject's receiving a
packed red blood cell (PREC) transfusion. The 57 TM subjects
consisted of 19 DFO users and 38 DFP users.
Results In our subjects, diastolic dysfunction was more commonly
seen than systolic dysfunction, especially moderate diastolic
dysfunction. In the DFO group, diastolic dysfunction only was
detected in 3/19 subjects, systolic dysfunction only in 1/19 subjects,
and both diastolic and systolic dysfunction in 15/19 subjects. None
of the DFO users had normal cardiac function. In the DFP group,
diastolic dysfunction only was seen in 6/38 subjects, and both
diastolic and systolic dysfunction in 30/38 subjects, while 2/38
subjects had normal cardiac function.
Conclusion Diastolic and/or systolic dysfunction was detected in
the majority of subjects, but with preserved global cardiac function.
We found that cardiac dysfunction was not significantly different in
the two iron chelator groups. For all subjects, diastolic dysfunction
was seen in 89% of cases, while systolic dysfunction was detected
in 77% of cases. [Paediatr Indones. 2012;52:272,9]. |
---|---|
ISSN: | 0030-9311 2338-476X |